Advanced Renal Cell Carcinoma: Integrating Prior Adjuvant Immunotherapy into First-Line Treatment Decisions

Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management of advanced renal cell carcinoma (RCC). He reviews the clinical evidence supporting adjuvant pembrolizumab following nephrectomy for patients with high-risk localized disease and contrasts these findings with other adjuvant immunotherapy studies that have not demonstrated similar benefit. Dr. Pal explains how a patient's prior exposure to immunotherapy influences his approach to first-line treatment selection after metastatic recurrence, emphasizing the importance of the interval between completion of adjuvant therapy and disease recurrence. He describes situations in which immunotherapy rechallenge may be appropriate and discusses circumstances where a tyrosine kinase inhibitor alone may be preferred because of concerns regarding early relapse following adjuvant treatment. This segment highlights the growing complexity of treatment sequencing in advanced renal cell carcinoma and underscores the importance of tailoring therapy based on prior treatment history, timing of recurrence, and individual patient characteristics.